Referred to the House Committee on Transportation and Infrastructure.
Requires the FAA Administrator to publish and maintain a publicly available list of medications and treatments the FAA uses when issuing airman medical certifications. The list must be drafted with specified stakeholder consultation, be user-friendly, show stabilization timeframes, include a “Do Not Issue” list, provide a clinician contact mechanism, and be updated annually.
Left emphasizes preventing stigmatization, especially mental-health drugs
Relative to its intended legislative type, this bill is a focused administrative directive that is generally well-specified in terms of required content, responsible actor, and timing, but it omits fiscal/resourcing acknowledgement and leaves some procedural and legal-effect details undefined.
Requires the FAA Administrator to publish and maintain a publicly available list of medications and treatments the FAA uses when issuing airman medical certifications.
The list must be drafted with specified stakeholder consultation, be user-friendly, show stabilization timeframes, include a “Do Not Issue” list, provide a clinician contact mechanism, and be updated annually.
Narrow, technical, low-cost transparency reform typically fares well; success depends on legislative calendar and absence of competing priorities.
Relative to its intended legislative type, this bill is a focused administrative directive that is generally well-specified in terms of required content, responsible actor, and timing, but it omits fiscal/resourcing acknowledgement and leaves some procedural and legal-effect details undefined.
Left emphasizes preventing stigmatization, especially mental-health drugs
These are examples from the analysis, not a ranked list of the most-affected groups.
Left emphasizes preventing stigmatization, especially mental-health drugs
Likely supportive because the bill increases transparency around health standards for airmen and can improve access to clear medical guidance.
Will push for inclusive stakeholder input and protections so the list doesn’t become a tool to deny necessary care, especially for mental-health medications.
Generally favorable as a pragmatic transparency and safety measure with limited scope.
Wants clarity on implementation, timelines, costs, and appeals to avoid unintended certification delays or administrative backlog.
Cautiously supportive of transparency but concerned about new bureaucratic obligations and potential negative effects on workforce flexibility.
Prefers physician judgment and minimal added federal mandates or liabilities for the FAA.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, technical, low-cost transparency reform typically fares well; success depends on legislative calendar and absence of competing priorities.
The bill has not accumulated any surfaced votes yet.
Left emphasizes preventing stigmatization, especially mental-health drugs
Narrow, technical, low-cost transparency reform typically fares well; success depends on legislative calendar and absence of competing prio…
Relative to its intended legislative type, this bill is a focused administrative directive that is generally well-specified in terms of required content, responsible actor, and timing, but it omits fiscal/resourcing ack…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.